Page 1,911«..1020..1,9101,9111,9121,913..1,9201,930..»

Inhibikase Wins $433000 MJFF Grant to Study c-Abl Inhibitors as Parkinson’s Treatment – Genetic Engineering & Biotechnology News (press release)

Posted: Published on March 9th, 2017

Inhibikase Therapeutics said today it has been awarded a $433,000 research grant from The Michael J. Fox Foundation for Parkinsons Research (MJFF) toward pre-IND studies of the companys novel Abelson tyrosine kinase (c-Abl) inhibitors as a potential Parkinsons disease (PD) treatment. Inhibikase has discovered and developed a series of c-Abl inhibitors using its proprietary Re-engineering Approach with Metabolism Preserved (RAMP) technology engine, and said it has validated their activity in preclinical animal models for multiple therapeutic indications in the brain. The company evaluated its RAMP molecules in preclinical animal models of PD. Results from those models showed that the molecules are capable of blocking the progressive death of dopamine-producing neurons that drives the disease, according to Inhibikase. The grant will support studies of the activity and pharmacology of the RAMP molecules in a newly defined mouse model designed to recapitulate many of the hallmarks of the progressive disease process in humans. The company said RAMP molecules that pass these tests will be positioned to advance into clinical testing. The research will supplement two recently launched clinical proof-of-principle studies designed to evaluate commercial anticancer c-Abl inhibitors as potential bridging therapies in PD until the companys RAMP molecules reach clinical testing in … Continue reading →

Posted in Parkinson's Treatment | Comments Off on Inhibikase Wins $433000 MJFF Grant to Study c-Abl Inhibitors as Parkinson’s Treatment – Genetic Engineering & Biotechnology News (press release)

Portishead boy with cerebral palsy one step closer to life changing operation – Somerset Live

Posted: Published on March 9th, 2017

Comments(0) A nine year-old boy with cerebral palsy is a step closer to getting a life-changing operation. Josh Walters, who lives with his family in Portishead, was born almost 12 weeks premature. He has grown up with cerebral palsy and spastic diplegia in his lower body. Although the inspiring youngster is a Cub Scout and plays for his local youth football team, the condition means the muscles in his lower body are tight, limiting his mobility and putting pressure on his hips, knees and joints. Without treatment he faces an increased risk of hip dislocations, severe joint problems and arthritis in the future. It is hoped spinal surgery called Selective Dorsal Rhizotomy (SDR) will eliminate a majority, if not all, of his symptoms and prevent side affects in the future. MORE: Two schools receive threats, one has been evacuated The operation is not funded by the NHS and his parents Andrew and Emma have launched a fundraising campaign called Operation Josh to pay for the procedure and immediate rehabilitation. Mr Walters said: "We have worked tirelessly to launch Operation Josh in the community and through social media together with an intense fundraising schedule with the view to book Josh in … Continue reading →

Posted in Cerebral Palsy Treatment | Comments Off on Portishead boy with cerebral palsy one step closer to life changing operation – Somerset Live

Molecule discovery may lead to new drugs for brain and spinal cord injury – Medical News Today

Posted: Published on March 9th, 2017

A new study reveals that a small molecule produced by a fungus may stimulate the regeneration of axons - the slender, "thread-like projections that carry electrical signals" between nerve cells in the brain and spinal cord. The researchers believe that the discovery could lead to much needed new drugs that repair damage to the central nervous system. Axon damage is a feature of injury to the central nervous system, such as that which occurs in traumatic brain injury, stroke, and spinal cord injury. It is the main reason for disability that results from these conditions. Unfortunately, once they are damaged, axons do not regenerate easily. Also, recent research suggests that in the case of traumatic brain injury, axons can continue to degenerate even years after injury and may play a role in the development of Alzheimer's disease-like changes in the brain. The new study - led by McGill University in Montreal, Canada, and published in the journal Neuron - concerns a family of proteins called 14-3-3 that show some ability to protect nerve cells or neurons. Senior author Alyson Fournier, a professor of neurology and neurosurgery at McGill, heads a laboratory that has been investigating 14-3-3 and looking for ways … Continue reading →

Posted in Brain Injury Treatment | Comments Off on Molecule discovery may lead to new drugs for brain and spinal cord injury – Medical News Today

Senators Peters, Perdue Reintroduce No Hero Left Untreated Act – UPMatters.com

Posted: Published on March 9th, 2017

Like Local 3 News on Facebook: WASHINGTON, D.C. U.S. Senators Gary Peters (D-MI) and David Perdue (R-GA) have reintroduced theNo Hero Left Untreated Actto enhance medical care for Americas heroes. The bipartisan legislation would create a pilot program to test an innovative treatment called Magnetic e-Resonance Therapy for veterans to help treat post-traumatic stress disorder (PTSD), traumatic brain injury (TBI) and other mental health issues. Peters and Perdue are both members of the Senate Armed Services Committee, and Peters is a former Lt. Commander in the U.S. Navy Reserve. Veterans suffering from the devastating effects of PTSD, traumatic brain injury and military sexual trauma deserve to have the best, most cutting-edge treatment available,said Senator Peters, a former Lt. Commander in the U.S. Navy Reserve.Incorporating innovative new treatment options like Magnetic e-Resonance Therapy technology into VA medical centers has the potential to improve treatment for veterans and create meaningful change in their lives. We must honor and care for the women and men who have courageously served our country,said Senator Perdue, a member of the Armed Services Committee.This pilot program would provide our veterans with access to additional medical treatment options for neurological injuries and has earned the support of several … Continue reading →

Posted in Brain Injury Treatment | Comments Off on Senators Peters, Perdue Reintroduce No Hero Left Untreated Act – UPMatters.com

Neuralstem Announces Publication of NSI-566 Data in a Rodent Model of Traumatic Brain Injury – P&T Community

Posted: Published on March 9th, 2017

Neuralstem Announces Publication of NSI-566 Data in a Rodent Model of Traumatic Brain Injury P&T Community No long-term treatment beyond physical therapy is currently available to restore cognition after a traumatic brain injury. Transplantation of stem cells into the injured brain may allow a unique replacement therapy and fill a significant medical need.. and more » Original post: Neuralstem Announces Publication of NSI-566 Data in a Rodent Model of Traumatic Brain Injury - P&T Community … Continue reading →

Posted in Brain Injury Treatment | Comments Off on Neuralstem Announces Publication of NSI-566 Data in a Rodent Model of Traumatic Brain Injury – P&T Community

Controversial ‘liberation therapy’ fails to treat multiple sclerosis – Science Daily

Posted: Published on March 9th, 2017

Science Daily Controversial 'liberation therapy' fails to treat multiple sclerosis Science Daily Using venoplasty as an MS treatment was put forward by Dr. Paolo Zamboni of Italy, who asserted that narrowing of the veins in the neck could be causing iron to accumulate in the brain and spinal cord, triggering the autoimmune response. He called his ... Controversial Therapy Fails to Treat Multiple SclerosisManaged Care magazine all 2 news articles » See the rest here: Controversial 'liberation therapy' fails to treat multiple sclerosis - Science Daily … Continue reading →

Posted in MS Treatment | Comments Off on Controversial ‘liberation therapy’ fails to treat multiple sclerosis – Science Daily

Targeting cancer stem cells improves treatment effectiveness and prevents metastasis – Medical Xpress

Posted: Published on March 9th, 2017

March 9, 2017 Targeting cancer stem cells may be a more effective way to overcome cancer resistance and prevent the spread of squamous cell carcinomathe most common head and neck cancer and the second-most common skin cancer, according to a new study by cancer researchers at the UCLA School of Dentistry. Head and neck squamous cell carcinoma is a highly invasive form of cancer and frequently spreads to the cervical lymph nodes. Currently, cisplatin is the standard therapeutic drug used for people with HNSCC. Yet, more than 50 percent of people who take cisplatin demonstrate resistance to the drug, and they experience a recurrence of the cancer. The five-year survival rates remain sorely low and researchers still don't understand the underlying mechanisms behind head and neck squamous carcinoma. Therefore, said UCLA cancer biologist Dr. Cun-Yu Wang, who led the study, there's an urgent need to understand why people with this type of cancer are resistant to therapy and to develop new approaches for treating it. Wang's research is published online today in the peer-reviewed journal Cell Stem Cell. Cancer stem cells are known to be responsible for tumor formation and development; they also self-renew and tend to be unresponsive to … Continue reading →

Posted in Stem Cell Research | Comments Off on Targeting cancer stem cells improves treatment effectiveness and prevents metastasis – Medical Xpress

Kansas Stem Cell Center Close To First Clinical Trial – KMUW

Posted: Published on March 9th, 2017

An adult stem cell center established by the Kansas Legislature in 2013 is almost ready for its first clinical trial. Buddhadeb Dawn, executive director of the Midwest Stem Cell Therapy Center, told legislators Tuesday that the trial will focus on treating graft-versus-host disease and will begin after final approvals from the U.S. Food and Drug Administration. Our goal was to do this (trial) in January, but we got delayed because of different things, Dawn said during a hearing of the House Health and Human Services Committee. So we are now hoping to start it perhaps in summer. Based at the University of Kansas Medical Center in Kansas City, the stem cell center has analyzed trials done elsewhere and hosted a clinical trial sponsored by a biotech company that uses modified stem cells from bone marrow to treat stroke. But the graft-versus-host disease trial would be the first homegrown one. Graft-versus-host disease is a potential complication when a patient receives a transplant of tissue, like an organ or bone marrow, from another person. The disease occurs when transplanted tissue fights the patients natural immune system, potentially damaging the liver, skin or other areas. Its a rare illness, with about 20,000 cases … Continue reading →

Posted in Stem Cell Research | Comments Off on Kansas Stem Cell Center Close To First Clinical Trial – KMUW

Cellceutix Releases Preliminary Efficacy and Safety Data in Interim … – EconoTimes

Posted: Published on March 8th, 2017

Cellceutix Releases Preliminary Efficacy and Safety Data in Interim Analysis of First Two Cohorts in Phase 2 Trial of Brilacidin for the Induction of Remission of Mild-to-Moderate Ulcerative Colitis BEVERLY, Mass., March 08, 2017 -- Cellceutix Corporation, (OTCQB:CTIX) (the Company), a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, today announced interim results in the first two cohorts of its ongoing Phase 2a clinical trial of Brilacidin for the induction of remission of mild-to-moderate Ulcerative Colitis. Patient recruitment to the third cohort (highest dose) is currently underway. Patients include those with Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD). The ongoing Phase 2, open-label, Proof-of-Concept (PoC) trial comprises three sequential cohorts (6 patients per cohort), with progressive dose escalation by cohort50 mg (Cohort A), 100 mg (Cohort B), and 200 mg (Cohort C), respectively. Daily treatment with Brilacidin by enema administration is performed consecutively for 42 days. All twelve (12) patients across the first two cohorts have completed their full dosing schedules in the study. Comparison to baseline after six weeks of treatment showed: Measurements of drug concentrations in plasma continued to show limited systemic absorption of Brilacidin, with all values … Continue reading →

Posted in Ulcerative Colitis | Comments Off on Cellceutix Releases Preliminary Efficacy and Safety Data in Interim … – EconoTimes

New Drug Has Enormous Potential In Treating Spinal Injuries – Huffington Post Australia

Posted: Published on March 8th, 2017

Trials have begun on the use of an anti-inflammatory drug with potentially life-changing implications for the future of spinal injuries. Spinal cord injuries are different from many other injuries in that the damage to the tissues will often continue after the initial injury occurs. The swelling and inflammation accompanying such injuries has damaging effects on nerve tissue and, over time, can spread to surrounding healthy tissue. Dr Mark Ruitenberg, who is leading the trial, explained that the treatment aims to target this 'secondary phase' of spinal injuries, whereby the unaffected tissue surrounding the site of the primary, irreversible injury, begins to become damaged. "When the spinal cord gets injured...a lot of things happen including a lot of inflammation," Ruitenberg told The Huffington Post Australia. "This inflammation is having a negative impact on the tissue that is still preserved at the time of the injury. "The more tissue one loses, the less likely the prospects for a recovery of function." The drug -- which is actually made from purified antibodies found within our own blood -- can target this harmful inflammation, with researchers hopeful that it will aid in preventing the loss of healthy tissue. "There is a degree of damage … Continue reading →

Posted in Spinal Cord Injury Treatment | Comments Off on New Drug Has Enormous Potential In Treating Spinal Injuries – Huffington Post Australia

Page 1,911«..1020..1,9101,9111,9121,913..1,9201,930..»